Danco Laboratories Battles for Mifepristone Mail Access

Danco Laboratories has requested that the U.S. Supreme Court stay a ruling by an appeals court that temporarily halts mail-order access to the abortion drug mifepristone. The company is contesting this decision to maintain the availability of the medication through mail distribution.

Danco Laboratories has taken decisive action by filing an application with the U.S. Supreme Court. The pharmaceutical firm's move seeks a stay of an appeals court decision that puts a temporary hold on mail-order access to the abortion drug, mifepristone.

This appeal marks a critical moment in the ongoing legal battles over mifepristone, widely used in medical abortions. The contested ruling threatens the availability of the drug via mail, a method that has become crucial for accessing abortion care.

With this application, Danco Laboratories aims to secure the continued mail-order distribution of mifepristone, arguing the decision to restrict it places undue barriers on reproductive rights.